四联疗法治疗幽门螺旋杆菌相关性十二指肠球炎疗效分析(1)
摘 要：目的 比较标准四联与三联法治疗幽门螺旋杆菌相关性十二指肠球炎临床疗效。方法 选择2017年5月～2018年5月我院收治的幽门螺旋杆菌相关性十二指肠球炎患者96例，随机分为观察组和对照组，每组48例。观察组采用兰索拉唑、克拉霉素、阿莫西林、果胶铋标准四联治疗，对照组采用兰索拉唑、克拉霉素、阿莫西林标准三联治疗。比较两组患者Hp根除率、复发率及不良反应情况。结果 观察组患者Hp根除率为91.67%，高于对照组75.00%，差异具有统计学意义(P<0.05)。观察组患者Hp复发率为10.42%，低于对照组的20.83%，差异具有统计学意义(P<0.05)。观察组不良反应发生率为4.16%，低于对照组的6.25%，但组间比较，差异无统计学意义(P>0.05)。结论 标准四联疗法治疗幽门螺旋杆菌相关性十二指肠球炎，Hp根除率较高，复发率低，且不增加不良反应发生率。
关键词：幽门螺旋杆菌；十二指肠球炎；四联疗法；三联疗法
中图分类号：R574.51 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.17.042
, 百拇医药
文章编号：1006-1959(2018)17-0135-02
Abstract：Objective To compare the clinical efficacy of standard quadruple therapy and triple therapy in the treatment of Helicobacter pylori associated duodenal inflammation.Methods 96 patients with Helicobacter pylori associated duodenal inflammation admitted to our hospital from May 2017 to May 2018 were randomly divided into observation group and control group，48 cases in each group.The observation group was treated with lansoprazole，clarithromycin，amoxicillin and bismuth pectin standard quadruple therapy，while the control group was treated with lansoprazole，clarithromycin and amoxicillin standard triple therapy.Hp eradication rate，relapse rate and adverse reactions were compared between the two groups.Results The Hp eradication rate of the observation group was 91.67%，which was higher than that of the control group 75.00%，the difference was statistically significant(P<0.05).The recurrence rate of Hp in the observation group was 10.42%，which was lower than that in the control group 20.83%，the difference was statistically significant (P<0.05).The incidence of adverse reactions in the observation group was 4.16%，which was lower than 6.25% in the control group，but there was no significant difference between the groups(P>0.05).Conclusion Standard quadruple therapy for Helicobacter pylori associated duodenal inflammation has a high eradication rate，a low recurrence rate and no increase in the incidence of adverse reactions.
, 百拇医药
Key words：Helicobacter pylori；Duodenal inflammation；Quadruple therapy；Triple therapy
幽门螺旋杆菌(helicobacter pylori，Hp)是一种革兰氏阴性杆菌，是消化道疾病和复发的重要因素[1]。治疗上通过药物抑制细菌生长，常采用质子泵抑制剂加阿莫西林、克拉霉素三联疗法治疗Hp感染。然而随着该方案的广泛应用，耐药问题逐渐突出，对Hp根除率已明显下降[2，3]。本文探讨标准四联疗法治疗幽门螺旋杆菌相关性十二指肠球炎的临床疗效及安全性，现报道如下。
1资料与方法
1.1一般资料 选择2017年5月～2018年5月武汉大学医院收治的幽门螺旋杆菌相关性十二指肠球炎患者96例，采用随机数字表法分为观察组和对照组，每组48例。观察组男22例，女26例；年龄29～55岁，平均年齡(38.61±1.32)岁；病程3个月～7年，平均病程(2.23±0.83)年。对照组男25例，女23例；年龄30～58岁，平均年龄(39.62±1.13)岁；病程4个月～8年，平均病程(3.23±0.62)年。两组患者的Hp检查均为阳性。两组患者的性别、年龄、病程等基线资料比较，差异无统计学意义(P>0.05)，有可比性。, 百拇医药(侯拂晓)
关键词：幽门螺旋杆菌；十二指肠球炎；四联疗法；三联疗法
中图分类号：R574.51 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.17.042
, 百拇医药
文章编号：1006-1959(2018)17-0135-02
Abstract：Objective To compare the clinical efficacy of standard quadruple therapy and triple therapy in the treatment of Helicobacter pylori associated duodenal inflammation.Methods 96 patients with Helicobacter pylori associated duodenal inflammation admitted to our hospital from May 2017 to May 2018 were randomly divided into observation group and control group，48 cases in each group.The observation group was treated with lansoprazole，clarithromycin，amoxicillin and bismuth pectin standard quadruple therapy，while the control group was treated with lansoprazole，clarithromycin and amoxicillin standard triple therapy.Hp eradication rate，relapse rate and adverse reactions were compared between the two groups.Results The Hp eradication rate of the observation group was 91.67%，which was higher than that of the control group 75.00%，the difference was statistically significant(P<0.05).The recurrence rate of Hp in the observation group was 10.42%，which was lower than that in the control group 20.83%，the difference was statistically significant (P<0.05).The incidence of adverse reactions in the observation group was 4.16%，which was lower than 6.25% in the control group，but there was no significant difference between the groups(P>0.05).Conclusion Standard quadruple therapy for Helicobacter pylori associated duodenal inflammation has a high eradication rate，a low recurrence rate and no increase in the incidence of adverse reactions.
, 百拇医药
Key words：Helicobacter pylori；Duodenal inflammation；Quadruple therapy；Triple therapy
幽门螺旋杆菌(helicobacter pylori，Hp)是一种革兰氏阴性杆菌，是消化道疾病和复发的重要因素[1]。治疗上通过药物抑制细菌生长，常采用质子泵抑制剂加阿莫西林、克拉霉素三联疗法治疗Hp感染。然而随着该方案的广泛应用，耐药问题逐渐突出，对Hp根除率已明显下降[2，3]。本文探讨标准四联疗法治疗幽门螺旋杆菌相关性十二指肠球炎的临床疗效及安全性，现报道如下。
1资料与方法
1.1一般资料 选择2017年5月～2018年5月武汉大学医院收治的幽门螺旋杆菌相关性十二指肠球炎患者96例，采用随机数字表法分为观察组和对照组，每组48例。观察组男22例，女26例；年龄29～55岁，平均年齡(38.61±1.32)岁；病程3个月～7年，平均病程(2.23±0.83)年。对照组男25例，女23例；年龄30～58岁，平均年龄(39.62±1.13)岁；病程4个月～8年，平均病程(3.23±0.62)年。两组患者的Hp检查均为阳性。两组患者的性别、年龄、病程等基线资料比较，差异无统计学意义(P>0.05)，有可比性。, 百拇医药(侯拂晓)